TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11867940

Group type: EXPERIMENTAL
Intervention: CRH test in obese patients (13 total: 5 men and 8 women)
Number of subjects: 39

Group type: COMPARATOR
Intervention: CRH test in control subjects (18 total: 9 men and 9 women)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CRH administration in obese subjects
Number of subjects: 39

Group type: COMPARATOR
Intervention: CRH administration in control subjects
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CRH test in obese patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CRH test in both groups
Number of subjects: 39
Study: 12953999

Group type: EXPERIMENTAL
Intervention: Heparin treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 8
Study: 7614110

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 30
Study: 2183758

Group type: EXPERIMENTAL
Intervention: Progressive Deep Muscle Relaxation Training
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Graduated Exposure
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Paradoxical Intention
Number of subjects: 88
Study: 7416212

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (Depo‐Provera)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29803203

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei (108 cfu daily for 8 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (maltodextrin capsules for 8 weeks)
Number of subjects: 40
Study: 26773206

Group type: EXPERIMENTAL
Intervention: Threat anticipation condition (anticipation of public speaking)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 168
Study: 25794163

Group type: EXPERIMENTAL
Intervention: CMV-naïve
Number of subjects: 107

Group type: COMPARATOR
Intervention: CMV+ viremic
Number of subjects: 107

Group type: COMPARATOR
Intervention: CMV+ aviremic
Number of subjects: 107

Group type: COMPARATOR
Intervention: CMV status
Number of subjects: 107
Study: 23361469

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Facemask with oropharyngeal airway (FM)
Number of subjects: 100
Study: 21381967

Group type: EXPERIMENTAL
Intervention: Playing Grand Theft Auto IV for a total of 12 hours over a period of 3 weeks
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no game played)
Number of subjects: 135
Study: 19531876

Group type: EXPERIMENTAL
Intervention: Observation with intent to imitate (OTI)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Imitation with real-time virtual avatar feedback
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Observation with intent to imitate actions performed by the virtual avatar
Number of subjects: 13

Group type: COMPARATOR
Intervention: Imitation with virtual avatar feedback
Number of subjects: 13
Study: 18605145

Group type: EXPERIMENTAL
Intervention: Feedback training on time-judgment task
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback training on time-judgment task
Number of subjects: 0
Study: 16360445

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 655

Group type: COMPARATOR
Intervention: Autologous rectus fascial sling
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Both surgical procedures
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Preoperative urodynamic studies
Number of subjects: 655
Study: 11887517

Group type: EXPERIMENTAL
Intervention: Crest SpinBrush
Number of subjects: 59

Group type: COMPARATOR
Intervention: Colgate Actibrush
Number of subjects: 59
Study: 10442383

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy combined with pelvic radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Number of subjects: 0
Study: 7625793

Group type: EXPERIMENTAL
Intervention: Cefdinir 200 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cefdinir 300 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cefdinir 400 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cefdinir 600 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cefdinir (all doses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cefdinir (200 to 400 mg administered twice daily)
Number of subjects: 16
Study: 2653046

Group type: COMPARATOR
Intervention: Topical corticosteroids only (Group A)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Topical and systemic corticosteroids (Group B)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Systemic cyclosporine with topical and systemic corticosteroids (Group C)
Number of subjects: 57
Study: 333079

Group type: EXPERIMENTAL
Intervention: Tolmetin sodium
Number of subjects: 137

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 137
Study: 31774581

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (inOT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 31
Study: 30706652

Group type: EXPERIMENTAL
Intervention: Itopride 50 mg (I50)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg (D10)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Itopride 100 mg (I100)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 15
Study: 28508529

Group type: EXPERIMENTAL
Intervention: Random practice group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Blocked practice group
Number of subjects: 42
Study: 26422095

Group type: EXPERIMENTAL
Intervention: Esomeprazole 5 or 10 mg daily (<20 kg) or 10 or 20 mg daily (>20 kg) for 8 weeks
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 109
Study: 23427965

Group type: EXPERIMENTAL
Intervention: Celox
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: ChitoGauze
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combat Gauze
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: HemCon wafer
Number of subjects: 45

Group type: COMPARATOR
Intervention: Prior medical training
Number of subjects: 45
Study: 21097785

Group type: EXPERIMENTAL
Intervention: Topical 0.1% micafungin (MCFG)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Topical 0.2% fluconazole (FCZ)
Number of subjects: 29
Study: 19052139

Group type: EXPERIMENTAL
Intervention: PACAP38 infusion (10 pmol/kg/min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PACAP38 infusion
Number of subjects: 24
Study: 16696581

Group type: EXPERIMENTAL
Intervention: Zolpidem CR (12.5mg for younger adults, 6.25mg for elderly patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zolpidem CR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15097955

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 436

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 436
Study: 11930695

Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 100

Group type: COMPARATOR
Intervention: TCu 380A
Number of subjects: 100
Study: 9326194

Group type: EXPERIMENTAL
Intervention: mercaptopurine (lower doses)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: early intensification treatment
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: myelosuppression during treatment
Number of subjects: 740
Study: 8173926

Group type: EXPERIMENTAL
Intervention: Double-contrast barium enema
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Both methods (barium enema and flexible sigmoidoscopy)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Barium enema
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Fibreoptic sigmoidoscopy before barium enema
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 462
Study: 2853091

Group type: EXPERIMENTAL
Intervention: Acebutolol (A) 400 mg once-daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Enalapril (E) 20 mg once-daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of Acebutolol and Enalapril (A + E)
Number of subjects: 12
Study: 29880292

Group type: EXPERIMENTAL
Intervention: ABP 980
Number of subjects: 725

Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: trastuzumab to ABP 980
Number of subjects: 725
Study: 28070747

Group type: EXPERIMENTAL
Intervention: Nuedexta (dextromethorphan and quinidine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25702144

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Intensive nutritional care (INC)
Number of subjects: 63
Study: 24200275

Group type: EXPERIMENTAL
Intervention: Myrin®-P Forte (FDC tablet containing rifampicin 150 mg, isoniazid 75 mg, ethambutol hydrochloride 275 mg, pyrazinamide 400 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Individual products in loose combination (rifampicin, isoniazid, ethambutol hydrochloride, pyrazinamide)
Number of subjects: 36
Study: 21169471

Group type: EXPERIMENTAL
Intervention: Inhaled denufosol, 60 mg, three times daily (n = 178)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo (n = 174)
Number of subjects: 352
Study: 18658109

Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam lysine (AZLI) 75 mg, twice or three times daily for 28 days
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Inhaled aztreonam lysine (AZLI) 75 mg
Number of subjects: 211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study: 17196057

Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 46
Study: 15490889

Group type: EXPERIMENTAL
Intervention: Early reading intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal IQ, phonological skills, orthographic skills, rapid automatized naming (RAN), and attention ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbal IQ-word reading discrepancy
Number of subjects: 0
Study: 11092660

Group type: EXPERIMENTAL
Intervention: MIDCAB
Number of subjects: 0

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 0
Study: 8957034

Group type: EXPERIMENTAL
Intervention: Low-dose ramipril (1.25 mg/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose ramipril (5 mg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1550063

Group type: EXPERIMENTAL
Intervention: 1758 kJ/d (420 kcal/d)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 2763 kJ/d (660 kcal/d)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 3349 kJ/d (800 kcal/d)
Number of subjects: 76
Study: 2862800

Group type: EXPERIMENTAL
Intervention: Methadone plus neuroleptic
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 30615491

Group type: EXPERIMENTAL
Intervention: Rigid taping
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no taping)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 72
Study: 27164676

Group type: EXPERIMENTAL
Intervention: Traumatic brain injury patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study: 24059806

Group type: EXPERIMENTAL
Intervention: KC‐1317 (a symbiotic mixture containing Saccharomyces boulardii lysate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22446739

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Number of subjects: 2591

Group type: EXPERIMENTAL
Intervention: Proactive counselling
Number of subjects: 2591

Group type: COMPARATOR
Intervention: Standard support
Number of subjects: 2591

Group type: COMPARATOR
Intervention: Standard support with nicotine replacement therapy
Number of subjects: 2591

Group type: COMPARATOR
Intervention: No nicotine replacement therapy
Number of subjects: 2591
Study: 20735791

Group type: EXPERIMENTAL
Intervention: Silodosin (4 mg, twice daily for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamsulosin (0.2 mg, once daily for 4 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Silodosin (after crossover)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamsulosin (after crossover)
Number of subjects: 0
Study: 18597909

Group type: EXPERIMENTAL
Intervention: INION system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Titanium miniplates
Number of subjects: 60
Study: 15702440

Group type: EXPERIMENTAL
Intervention: rhGH in combination with metformin (MGH)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Metformin + Placebo (MP)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study: 12541165

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg/die
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ceftriaxone 2 g/die
Number of subjects: 60
Study: 10877410

Group type: EXPERIMENTAL
Intervention: 3D ultrasound (3D US)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (TIPS without 3D US)
Number of subjects: 20
Study: 8932974

Group type: EXPERIMENTAL
Intervention: BARI hotline for recruitment support
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: BARI hotline for patient randomization backup
Number of subjects: 1332

Group type: EXPERIMENTAL
Intervention: BARI hotline for protocol clarification
Number of subjects: 1332
Study: 1813436

Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) at 3 mg/kg/day for 5 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) at 5 mg/kg/day for 5 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) at 7 mg/kg/day for 5 days
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 15-deoxyspergualin (DSG) at 3-5 mg/kg/day
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Adverse reactions
Number of subjects: 66
Study: 6613913

Group type: EXPERIMENTAL
Intervention: 125 mg daily dietary aluminum (test diet)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 5 mg daily dietary aluminum (control diet)
Number of subjects: 8
Study: 31028327

Group type: EXPERIMENTAL
Intervention: High-viscosity glass-ionomer, atraumatic restorative treatment method (HVGIC/ART)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Thermo-cured HVGIC/ART
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Glass-carbomer
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Resin composite
Number of subjects: 405

Group type: COMPARATOR
Intervention: Micro-cavitated dentine carious lesions (baseline code 2)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Sealed over micro-cavitated dentine carious lesions
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Sealed over dentine lesions with a small orifice (Ø <0.5 mm)
Number of subjects: 405
Study: 28655834

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13130

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13130
Study: 25351652

Group type: EXPERIMENTAL
Intervention: Legume-based TLC diet (substituting two servings of red meat with legumes, 3 days per week)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Legume-free TLC diet
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Legume-based TLC diet
Number of subjects: 31
Study: 23669281

Group type: EXPERIMENTAL
Intervention: YIC (HBsAg-HBIG immunogenic complex therapeutic vaccine)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Alum (placebo)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: YIC
Number of subjects: 450

Group type: COMPARATOR
Intervention: Alum
Number of subjects: 450
Study: 21616200

Group type: EXPERIMENTAL
Intervention: δ¹³C value of fingerstick blood
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lowest tertile of added-sugar intake
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mean added-sugar consumption
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mean sugar-sweetened beverage consumption
Number of subjects: 60
Study: 19176737

Group type: COMPARATOR
Intervention: Standard treatment with high-dose iron-folic acid for 90 days and single-dose (500 mg) mebendazole
Number of subjects: 6288

Group type: EXPERIMENTAL
Intervention: Enhanced treatment with 100 mg mebendazole twice daily for 3 days
Number of subjects: 6288

Group type: EXPERIMENTAL
Intervention: 90 days of daily multivitamins
Number of subjects: 6288

Group type: EXPERIMENTAL
Intervention: Combination of enhanced mebendazole and multivitamins
Number of subjects: 6288
Study: 17971666

Group type: EXPERIMENTAL
Intervention: 150 mg GGA t.i.d. for 2 weeks
Number of subjects: 128

Group type: COMPARATOR
Intervention: 400 mg CIT b.i.d. for 2 weeks
Number of subjects: 128
Study: 15600244

Group type: EXPERIMENTAL
Intervention: Antifungal agents
Number of subjects: 0
Study: 15153583

Group type: EXPERIMENTAL
Intervention: Functional foot orthoses
Number of subjects: 48

Group type: COMPARATOR
Intervention: Accommodative foot orthoses
Number of subjects: 48
Study: 10734666

Group type: EXPERIMENTAL
Intervention: Ozone exposure (0.22 ppm for four hours with exercise)
Number of subjects: 27
Study: 7627383

Group type: EXPERIMENTAL
Intervention: Octreotide (0.1 mg injected subcutaneously three times a day)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (conservative treatment alone)
Number of subjects: 38
Study: 1790735

Group type: EXPERIMENTAL
Intervention: Ponalrestat (600 mg daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 7041934

Group type: EXPERIMENTAL
Intervention: ibopamine (SB 7505, a new oral dopaminergic drug)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: frusemide
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 30426166

Group type: EXPERIMENTAL
Intervention: Afternoon high-intensity interval training (HIIT)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Morning high-intensity interval training (HIIT)
Number of subjects: 11
Study: 28796888

Group type: EXPERIMENTAL
Intervention: full-mouth disinfection (FDIS) + MTZ
Number of subjects: 184

Group type: COMPARATOR
Intervention: full-mouth disinfection (FDIS) + placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: scaling and root planing + MTZ
Number of subjects: 184

Group type: COMPARATOR
Intervention: scaling and root planing + placebo
Number of subjects: 184
Study: 26928164

Group type: EXPERIMENTAL
Intervention: Suboccipital inhibitory pressure
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Suboccipital spinal manipulation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Combination of suboccipital inhibitory pressure and spinal manipulation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 24276907

Group type: EXPERIMENTAL
Intervention: Madres a Madres program (intervention group with 113 mother-child dyads)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Wait-list control condition (control group with 81 mother-child dyads)
Number of subjects: 194
Study: 21345928

Group type: EXPERIMENTAL
Intervention: Extraction of four deciduous canines
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no extraction)
Number of subjects: 73
Study: 19618661

Group type: EXPERIMENTAL
Intervention: Cyproheptadine administration (n = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n = 11)
Number of subjects: 21
Study: 17479573

Group type: EXPERIMENTAL
Intervention: KR good (knowledge of results after good trials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: KR poor (knowledge of results after poor trials)
Number of subjects: 0
Study: 15710814

Group type: EXPERIMENTAL
Intervention: Bimatoprost
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Unoprostone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lubricant drops (Control)
Number of subjects: 80
Study: 15002546

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of a balanced mixture of essential and non-essential amino acids at a rate of 0.1 g/kg/hour for 3 hours.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ambulatory group (control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bed rest group
Number of subjects: 0
Study: 9891949

Group type: EXPERIMENTAL
Intervention: Elite baseball players
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy sedentary subjects
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Elite baseball players and Healthy sedentary subjects
Number of subjects: 20
Study: 7625114

Group type: EXPERIMENTAL
Intervention: Intranasal administration of trivalent cold-adapted recombinant influenza virus vaccine containing type A (H1N1 and H3N2) and B viruses.
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Intranasal administration of trivalent cold-adapted recombinant influenza virus vaccine.
Number of subjects: 128
Study: 31524645

Group type: EXPERIMENTAL
Intervention: Massage only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupressure only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Massage + Acupressure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 120
Study: 31464642

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 1141

Group type: COMPARATOR
Intervention: Control (bPI + emtricitabine/tenofovir disoproxil fumarate)
Number of subjects: 1141
Study: 27701952

Group type: EXPERIMENTAL
Intervention: Add-on mirtazapine
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 26036479

Group type: EXPERIMENTAL
Intervention: IGL-1
Number of subjects: 178

Group type: COMPARATOR
Intervention: HTK
Number of subjects: 178
Study: 23239694

Group type: EXPERIMENTAL
Intervention: Gated MRI
Number of subjects: 53

Group type: COMPARATOR
Intervention: 4D-CT
Number of subjects: 53
Study: 20170948

Group type: EXPERIMENTAL
Intervention: benazepril (20 mg) plus amlodipine (5 mg)
Number of subjects: 11506

Group type: COMPARATOR
Intervention: benazepril (20 mg) plus hydrochlorothiazide (12.5 mg)
Number of subjects: 11506
Study: 17526983

Group type: EXPERIMENTAL
Intervention: Unipolar plus bipolar recording (Uni-group; n=18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bipolar recording (Bi-group; n=18)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unipolar His bundle recordings in Uni-group
Number of subjects: 36